Revenues - Additional Information (Detail)	1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2022 USD ($)	Jan. 31, 2020 USD ($) Kilograms	Mar. 31, 2019 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Disaggregation of Revenue [Line Items]
Revenue					$ 5,000	$ 5,000	$ 15,000	$ 3,765,000
Deferred revenue					100,000		100,000		$ 100,000
2017 Allergan Agreement [Member]
Disaggregation of Revenue [Line Items]
Cash payment received				$ 11,000,000
Potential additional payments				5,500,000
2019 Allergan Amendment Agreement [Member]
Disaggregation of Revenue [Line Items]
One-time payment			$ 7,500,000
2020 Allergan Amendment Agreement [Member]
Disaggregation of Revenue [Line Items]
Revenue					0	0	0	0
Up front payment received		$ 1,000,000
Additional quantity of product to be supplied | Kilograms		200
Revenue related to Potential Future Improvements		$ 200,000
Revenue recognized					5,000		15,000
2022 Allergan Letter Agreement [Member]
Disaggregation of Revenue [Line Items]
Potential milestone payment				5,500,000
Potential milestone payment recognized	$ 3,800,000
Product [Member] | 2017 Allergan Agreement [Member] | Minimum [Member]
Disaggregation of Revenue [Line Items]
Sales target for additional potential payment payout				60,000,000
Product [Member] | 2022 Allergan Letter Agreement [Member] | Minimum [Member]
Disaggregation of Revenue [Line Items]
Sales target for potential milestone payment				$ 60,000,000
License [Member]
Disaggregation of Revenue [Line Items]
Revenue					$ 5,000	$ 5,000	$ 15,000	$ 3,765,000
License [Member] | 2019 Allergan Amendment Agreement [Member]
Disaggregation of Revenue [Line Items]
Revenue			$ 7,500,000
License [Member] | 2022 Allergan Letter Agreement [Member]
Disaggregation of Revenue [Line Items]
Revenue									$ 3,800,000